Nivolumab-caused hyperprogression of diffuse large B-cell lymphoma of the testis and spontaneous remission of type 2 diabetes mellitus in an elderly patient: a case report. Issue 5 (15th February 2021)

• Record Type: Journal Article
• Authors: Zhang, Xue; Jiang, Da; Huang, Fang; Wang, Zhe; Jin, Hui; Cui, Yanzhi; Fan, Shaoshuang
• Is Part Of: Anti-cancer drugs. Volume 32:Issue 5(2021)
• Page Start: 575
• Page End: 579
• Publication Date: 2021-02-15
• Subjects: diffuse large B-cell lymphoma -- hyperprogression -- nivolumab -- type 2 diabetes mellitus; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001033
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Nivolumab has been used in a variety of advanced malignant tumors. Cases of autoimmune diabetes associated with Nivolumab therapy have been reported gradually in recent years. This article reported a case of primary testicular lymphoma in an elderly patient with type 2 diabetes mellitus (T2DM). After treatment with Nivolumab, the primary disease was hyperprogressive disease but the blood glucose was relieved for a long time. Nivolumab may relieve the previous T2DM in diffuse large B-cell lymphoma patients; the potential mechanism needs to be further explored.